2025
Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216).
Pinski J, Ingles S, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Androgen pathway gene expression and response to hormonal therapy in prostate cancer (SWOG S1216). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e17109.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerProgression free survivalResponse to androgen deprivation therapyAndrogen metabolism genesAndrogen deprivation therapyPrimary prostate tumorsProstate cancerPSA responsePSA-CRDeprivation therapyProstate tumorsMolecular features of prostate cancerCastration-sensitive prostate cancerAnalysis of progression free survivalFeatures of prostate cancerResponse to hormonal therapyDays of follow-upAndrogen receptor inhibitorsTumor gene expression profilesUnder-expressedExpression levelsFree survivalAssociation of expression levelsHormone therapyTumor blocks
2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study
Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo P, Zanardi E, Rossetti S, Davidsohn M, Eid M, Zarif T, McClure H, Spinelli G, Damassi A, Murianni V, Vauchier C, Oliveira T, Malgeri A, Modesti M, Mestre R, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E, Group S. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study. Clinical Genitourinary Cancer 2024, 22: 102185. PMID: 39217072, DOI: 10.1016/j.clgc.2024.102185.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerMetastatic castration-resistant prostate cancerAbiraterone acetate plus prednisoneAndrogen deprivation therapyCancer-specific survivalCastration-sensitive prostate cancerFirst-line therapyProstate cancerAdverse eventsFailure of androgen deprivation therapyMedian cancer-specific survivalCastration-resistant prostate cancerAcetate plus prednisoneInternational multicenter registryMedian Follow-UpKaplan-Meier methodFirst-line treatmentUpfront docetaxelDeprivation therapyAbiraterone acetatePrimary endpointSurvival outcomesMulticenter registryADT+DFollow-up
2023
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.
Naqvi S, Riaz I, He H, Imran M, Orme J, Childs D, Ravi P, Hussain S, Singh P, Bryce A. The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis. Journal Of Clinical Oncology 2023, 41: 5088-5088. DOI: 10.1200/jco.2023.41.16_suppl.5088.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerVolume of diseaseTriplet therapyDoublet therapyLV diseaseHazard ratioCastration-sensitive prostate cancerSensitive prostate cancerLow-volume diseaseEfficacious treatment optionConfidence intervalsInverse variance approachMixed treatment comparisonMCSPC patientsTreatment intensificationTreatment optionsClinical trialsProstate cancerEfficacious treatmentTreatment selectionDisease subgroupsPatientsComparative effectivenessTherapyDiseaseFirst-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
Bin Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs D, Ravi P, Hussain S, Murad M, Boorjian S, Sweeney C, Van Allen E, Bryce A. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology 2023, 9: 635-645. PMID: 36862387, PMCID: PMC9982744, DOI: 10.1001/jamaoncol.2022.7762.Peer-Reviewed Original ResearchConceptsMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerAndrogen pathway inhibitorsSystemic treatment optionsProgression-free survivalOverall survivalTreatment optionsClinical trialsTriplet therapyProstate cancerFirst-line systemic treatment optionComparative effectivenessFirst-line treatment optionHigh-volume diseaseHigher adverse eventsImproved overall survivalLow-volume diseaseHealth-related qualityFuture clinical trialsDifferent treatment optionsHeterogeneous patient populationVolume of diseaseOutcomes of interestTriplet regimensEligible RCTsA living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).
Bin Riaz I, Naqvi S, He H, Siddiqi R, Asghar N, Ravi P, Hussain S, Singh P, Bryce A. A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC). Journal Of Clinical Oncology 2023, 41: 193-193. DOI: 10.1200/jco.2023.41.6_suppl.193.Peer-Reviewed Original ResearchProgression-free survivalMetastatic castration-sensitive prostate cancerAndrogen pathway inhibitorsMCSPC patientsTriplet regimensHazard ratioSignificant improved progression-free survivalCastration-sensitive prostate cancerImproved progression-free survivalSubgroup dataOverall patient populationTiming of metastasisConfidence intervalsVolume of diseaseMixed treatment comparisonEvidence synthesis frameworkSTAMPEDE trialTreatment intensificationTriplet regimenDisease volumeMetastatic presentationSystemic therapyOptimal therapyRandomized comparisonPatient population
2022
1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review
Riaz I, Naqvi S, He H, Asghar N, Siddiqi R, Khakwani K, Liu H, Hussain S, Singh P, Murad M, Bryce A. 1417P Mixed treatment comparisons evaluating contemporary therapies in metastatic castration sensitive prostate cancer (mCSPC): A living systematic review. Annals Of Oncology 2022, 33: s1193. DOI: 10.1016/j.annonc.2022.07.1903.Peer-Reviewed Original ResearchMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerSensitive prostate cancerMixed treatment comparisonContemporary therapyProstate cancerSystematic reviewTreatment comparisonsTherapyCancer
2016
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever
Tsao C, Galsky M, Oh W. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. European Urology 2016, 70: 707-708. PMID: 27417033, DOI: 10.1016/j.eururo.2016.06.041.Peer-Reviewed Original ResearchConceptsNeutropenic feverProstate cancerMetastatic castration-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerProphylactic granulocyte colony-stimulating factorCastration-sensitive prostate cancerRisk of neutropenic feverHormone-sensitive prostate cancerGranulocyte colony-stimulating factorCastration-resistant diseaseColony-stimulating factorAssociated with higher ratesDocetaxel treatmentRisk factorsFeverCancerHigher RatesRiskNeutropeniaDocetaxel
2014
Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC)
Sonpavde G, Wang C, Galsky M, Oh W, Armstrong A. Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC). BJU International 2014, 116: 17-29. PMID: 25046451, DOI: 10.1111/bju.12867.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerManagement of metastatic castration-resistant prostate cancerTreatment of metastatic castration-resistant prostate cancerMetastatic castration-sensitive prostate cancerCastration-sensitive prostate cancerDevelopment of multiple agentsImproved survival of patientsResistance to available agentsOptimal sequence of treatmentOptimise treatment benefitTiming of chemotherapySurvival of patientsSelection of patientsManagement of patientsDeclining performance statusLong-term outcomesCytotoxic chemotherapySequence of treatmentPerformance statusPredictive biomarkersImproved survivalPatient selectionChemotherapeutic agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply